These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12567157)

  • 1. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report.
    Goëb JL; Cailleau A; Lainé P; Etcharry-Bouyx F; Maugin D; Duverger P; Gohier B; Rannou-Dubas K; Dubas F; Garré JB
    Clin Neuropharmacol; 2003; 26(1):5-7. PubMed ID: 12567157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis.
    Lana-Peixoto MA; Teixeira AL; Haase VG
    Arq Neuropsiquiatr; 2002 Sep; 60(3-B):721-4. PubMed ID: 12364937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric side effects of interferon-beta in multiple sclerosis.
    Goeb JL; Even C; Nicolas G; Gohier B; Dubas F; Garré JB
    Eur Psychiatry; 2006 Apr; 21(3):186-93. PubMed ID: 16386408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis.
    Patten SB; Francis G; Metz LM; Lopez-Bresnahan M; Chang P; Curtin F
    Mult Scler; 2005 Apr; 11(2):175-81. PubMed ID: 15794391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.
    Mohr DC; Likosky W; Dwyer P; Van Der Wende J; Boudewyn AC; Goodkin DE
    Arch Neurol; 1999 Oct; 56(10):1263-5. PubMed ID: 10520943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
    Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
    Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a.
    Tola MR; Caniatti LM; Gragnaniello D; Russo M; Stabellini N; Granieri E
    J Neurol; 2003 Jun; 250(6):768-9. PubMed ID: 12862038
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute hepatitis secondary to interferon beta-1a in multiple sclerosis.
    Christopher V; Scolding N; Przemioslo RT
    J Neurol; 2005 Jul; 252(7):855-6. PubMed ID: 15742101
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.
    Schott E; Paul F; Wuerfel JT; Zipp F; Rudolph B; Wiedenmann B; Baumgart DC
    World J Gastroenterol; 2007 Jul; 13(26):3638-40. PubMed ID: 17659718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
    Feinstein A; O'Connor P; Feinstein K
    J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status of interferon beta-1b in multiple sclerosis therapy].
    Hartung HP
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
    Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
    J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of interferons in the treatment of multiple sclerosis.
    Kelley CL
    J Neurosci Nurs; 1996 Apr; 28(2):114-20. PubMed ID: 8718760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors leading patients to discontinue multiple sclerosis therapies.
    Daugherty KK; Butler JS; Mattingly M; Ryan M
    J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
    Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
    J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.
    Murdoch D; Lyseng-Williamson KA
    Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a.
    Kumar N; Rodriguez M
    Mult Scler; 2004 Feb; 10(1):85-6. PubMed ID: 14760958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.